Launched in July 2020, Project ACTT is a federally-funded Canadian program providing circulating tumor DNA (ctDNA) testing as an alternative to surgical tissue biopsy for 2,000 patients with metastatic or recurrent breast, lung, and colorectal cancers. COVID-19 has made it clear ctDNA testing should be considered a first-line alternative when tissue biopsies are not available.
The Canadian Digital Technology Supercluster approved this initiative in support of a consortium led by Canexia Health to deploy and enhance its minimally-invasive ctDNA test. Partners include AstraZeneca Canada, Queen’s University, LifeLabs, Illumina, Eastern Ontario Regional Laboratory, and Genolife.
Read the Press Release